T1	Participants 115 183	patients with progressive hormone-escaped metastatic prostate cancer
T2	Participants 432 475	hormone refractory prostate cancer patients
T3	Participants 485 496	92 patients
T4	Participants 1642 1676	hormone refractory prostate cancer
